Targeting Upstream Mediators and the Airway Epithelium With Next-Generation Biologics




This program is provided by Integrity Continuing Education, Inc.


This program is supported by an educational grant from AstraZeneca Pharmaceuticals.


This interactive activity will provide relevant clinicians with a greater understanding of the unmet needs in severe asthma, the alarmin pathway, and novel biologic therapies and their potential positioning within the therapeutic landscape. This may lead to improved treatment practices and better outcomes for the broader severe asthma population.

After a brief lecture, learners will enter the virtual interactive exam room where they’ll have an opportunity to work through two standardized clinical cases.


Jonathan Corren, MD
Department of Medicine and Pediatrics
Division of Allergy & Immunology
David Geffen School of Medicine at UCLA
Los Angeles, California


Nicola A. Hanania, MD, MS 
Professor of Medicine
Director, Airways Clinical Research Center
Chief, PCCM, Ben Taub Hospital
Baylor College of Medicine
Houston, Texas


Release date: July 29, 2022
Expiration date: July 29, 2023
Estimated time to complete activity: 45 minutes



This activity is intended for US-based asthma specialists, including allergists, immunologists, and pulmonologists, as well as specialty nurse practitioners and physician assistants.


Upon completion of this educational activity, participants should be able to:

  • Describe the unmet needs with current severe asthma therapies and the contributions of the airway epithelium and hyperresponsiveness in the disease
  • Explain the involvement of alarmins in severe asthma and the rationale for targeting upstream cytokines in controlling the disease
  • Apply newly approved treatments that address the alarmin pathway in severe asthma in appropriate patient types

There are no fees for participating and receiving CME credit for this activity. During the period of July 15, 2022 through July 15, 2023 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Jonathan Corren, MD
Consultant: AstraZeneca, Genentech, Regeneron, Sanofi
Contracted Research: AstraZeneca, Genentech, Regeneron, Sanofi
Speaker: AstraZeneca, Genentech, Regeneron, Sanofi

Nicola A. Hanania, MD, MS 
Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Mylan, Novartis, Sanofi, Teva
Research Support: AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Sanofi, Teva
Speaker: Sanofi

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest